Sijana Dzinic

Sijana Dzinic

Sijana Dzinic

Position Title

Assistant Professor - Research

Office Location

Karmanos Cancer Institute
Elliman Building, RM - 1107
421 E Canfield
Detroit, MI 48201

Mailing Address

Karmanos Cancer Institute
4100 John R., EL01AM
Detroit, MI 48201

Office Phone


Education Training

(2008) PhD, Summa Cum Laude, Wayne State University School of Medicine, Detroit, MI
(2003) BS, Summa Cum Laude, Wayne State University, Detroit, MI

Postgraduate Training
(2008 - 2011) Postdoctoral Fellow, Department of Pathology, Wayne State University, Detroit, MI

Professional Experience

Faculty Appointments
(2022-Present) Assistant Professor - Research, Department of Oncology, Wayne State University School of Medicine ,Detroit, MI

Major Professional Societies

(2017 - Present) Molecular Therapeutics Program, Wayne State University
(2010 - Present) American Association for Cancer Research (AACR)
(2013 - Present) United States and Canadian Academy of Pathology (USCAP)
(2010 - Present) American Society for Microbiology




 Original Observations

Wallace-Povirk A, Rubinsak L, Malysa A, Dzinic SH, Ravindra M, Schneider M, Glassbrook J, O’Connor C, Hou Z, Kim S, Back J, Polin L, Morris RT, Gangjee A, Gibson H, Matherly LH. Targeted therapy of pyrrolo[2,3- d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. Scientific Report, manuscript under revision.

Qiao X, Ma J, Knight T, Su Y, Edwards H, Polin L, Li J, Kushner J, Dzinic SH, White K, Wang J, Lin H, Wang Y, Wang L, Wang G, Taub JW, Ge Y. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer J. 2021 Jun 7;11(6):111. doi: 10.1038/s41408-021-00502-7. PMID: 34099621; PMCID: PMC8184771.

Rumman M, Buck S, Polin L, Dzinic SH, Boerner J, Winer IS. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. Cancer Med. 2021 May;10(10):3373-3387. doi: 10.1002/cam4.3858. Epub 2021 May 1. PMID: 33932119; PMCID: PMC8124100.

Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, Yang J, Miller R, Wang G, Zhao L, Wang Y, Lin H, Taub JW, Ge Y. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2021 May 1;106(5):1262-1277. doi:10.3324/haematol.2019.233445. PMID: 32165486; PMCID: PMC8094102.

Liu F, Kalpage HA, Wang D, Edwards H, Hüttemann M, Ma J, Su Y, Carter J, Li X, Polin L, Kushner J, Dzinic SH, White K, Wang G, Taub JW, Ge Y. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers (Basel). 2020 Aug 24;12(9):2400. doi: 10.3390/cancers12092400. PMID: 32847115; PMCID: PMC7564145.

Venkatesh J, Sekhar SC, Cheriyan VT, Muthu M, Meister P, Levi E, Dzinic SH, Gauld JW, Polin LA, Rishi AK. Antagonizing binding of cell cycle and apoptosis regulatory protein 1 (CARP-1) to the NEMO/IKKγ protein enhances the anticancer effect of chemotherapy. J Biol Chem. 2020 Mar 13;295(11):3532-3552. doi: 10.1074/jbc.RA119.009898. Epub 2020 Feb 4. PMID: 32024692; PMCID: PMC7076213.

Luedtke DA, Su Y, Ma J, Li X, Buck SA, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Lin H, Taub JW, Ge Y. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020 Feb 26;5(1):17. doi: 10.1038/s41392-020-0112-3. PMID: 32296028; PMCID: PMC7042303.

Li X, Su Y, Madlambayan G, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Ma J, Knight T, Wang G, Wang Y, Yang J, Taub JW, Lin H, Ge Y. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Haematologica. 2019 Nov;104(11):2225-2240. doi: 10.3324/haematol.2018.201343. Epub 2019 Feb 28. PMID: 30819918; PMCID: PMC6821619.

Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18. PMID: 31320594; PMCID: PMC6858954.

Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Liu J, Wallace-Povirk A, O'Connor C, Dzinic SH, White K, Kushner J, Kim S, Hüttemann M, Polin L, Rabinowitz JD, Li J, Hou Z, Dann CE 3rd, Gangjee A, Matherly LH. Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy. Mol Cancer Ther. 2019 Oct;18(10):1787-1799. doi: 10.1158/1535-7163.MCT-19-0037. Epub 2019 Jul 9. PMID: 31289137; PMCID: PMC6774887.

Dzinic SH, Mahdi Z, Bernardo MM, Vranic S, Beydoun H, Nahra N, Alijagic A, Harajli D, Pang A, Saliganan DM, Rahman AM, Skenderi F, Hasanbegovic B, Dyson G, Beydoun R, Sheng S. Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma. PLoS One. 2019 Apr 19;14(4):e0215089. doi: 10.1371/journal.pone.0215089. PMID: 31002675; PMCID: PMC6474598.

Dean I, Dzinic SH, Bernardo MM, Zou Y, Kimler V, Li X, Kaplun A, Granneman J, Mao G, Sheng S. The secretion and biological function of tumor suppressor maspin as an exosome cargo protein. Oncotarget. 2017 Jan 31;8(5):8043-8056. doi: 10.18632/oncotarget.13302. PMID: 28009978; PMCID: PMC5352381.

Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, Vranic S, Oliveira DS, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M, Pang A, Harajli D, Sakr WA, Sheng S. An Essential Role of Maspin in Embryogenesis and Tumor Suppression. Cancer Res. 2017 Feb 15;77(4):886-896. doi: 10.1158/0008-5472.CAN-16-2219. Epub 2016 Dec 6. PMID: 27923833; PMCID: PMC5313336.

Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18. PMID: 26581400; PMCID: PMC6820516.

15. Bernardo MM, Kaplun A, Dzinic SH, Li X, Irish J, Mujagic A, Jakupovic B, Back JB, Van Buren E, Han X, Dean I, Chen YQ, Heath E, Sakr W, Sheng S. Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. Cancer Res. 2015 Sep 15;75(18):3970-9. doi: 10.1158/0008-5472.CAN-15-0234. Epub 2015 Jul 24. PMID: 26208903; PMCID: PMC4573892.

Lonardo F, Guan H, Dzinic SH, Sheng S. Maspin expression patterns differ in the invasive versus lepidic growth pattern of pulmonary adenocarcinoma. Histopathology. 2014 Dec;65(6):757-63. doi: 10.1111/his.12485. Epub 2014 Sep 9. PMID: 25040445; PMCID: PMC4245330.

Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S. Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget. 2014 Nov 30;5(22):11225-36. doi: 10.18632/oncotarget.2615. PMID: 25373490; PMCID: PMC4294340.

Dzinic SH, Kaplun A, Li X, Bernardo M, Meng Y, Dean I, Krass D, Stemmer P, Shin N, Lonardo F, Sheng S. Identification of an intrinsic determinant critical for maspin subcellular localization and function. PLoS One. 2013 Nov 21;8(11):e74502. doi: 10.1371/journal.pone.0074502. PMID: 24278104; PMCID: PMC3837015.

Wang Y, Sheng S, Zhang J, Dzinic SH, Li S, Fang F, Wu N, Zheng Q, Yang Y. Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC). PLoS One. 2013 May 22;8(5):e63581. doi: 10.1371/journal.pone.0063581. Erratum in: PLoS One. 2014;9(8):e104715. PMID: 23717449; PMCID: PMC3661574.

Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic SH, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S. Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2011 Nov;2(11):1009-22. doi: 10.1177/1947601912440170. PMID: 22737267; PMCID: PMC3379563.

Kato I, Nechvatal JM, Dzinic SH, Basson MD, Majumdar AP, Ram JL. Smoking and other personal characteristics as potential predictors for fecal bacteria populations in humans. Med Sci Monit. 2010 Jan;16(1):CR1-7. PMID: 20037488; PMCID: PMC4929991.

Dzinic SH, Luercio M, Ram JL. Bacterial chemotaxis differences in Escherichia coli isolated from different hosts. Can J Microbiol. 2008 Dec;54(12):1043-52. doi: 10.1139/W08-105. PMID: 19096459.

Dzinic SH, Shukla M, Mandija I, Ram TS, Ram JL. Variable length tandem repeat polyglutamine sequences in the flexible tether region of the Tsr chemotaxis receptor of Escherichia coli. Microbiology (Reading). 2008 Aug;154(Pt 8):2380-2386. doi: 10.1099/mic.0.2008/016303-0. PMID: 18667570

Soh JW, Hotic S, Arking R. Dietary restriction in Drosophila is dependent on mitochondrial efficiency and constrained by pre-existing extended longevity. Mech Ageing Dev. 2007 Nov-Dec;128(11-12):581-93. doi: 10.1016/j.mad.2007.08.004. Epub 2007 Aug 17. PMID: 17928035.

Faculty Status

Basic Science

← Return to listing